Hydrocodone controlled-release - Pernix Therapeutics

Drug Profile

Hydrocodone controlled-release - Pernix Therapeutics

Alternative Names: AFI-001; Hydrocodone bitartrate; Hydrocodone ER; Hydrocodone extended release; Zohydro ER; ZX 007; ZX-002

Latest Information Update: 15 Sep 2016

Price : $50

At a glance

  • Originator Daravita
  • Developer Altus Formulation Inc; Pernix Therapeutics Holdings; Zogenix
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 14 Sep 2016 Pernix Therapeutics has patent protection for controlled-release hydrocodone in USA
  • 09 Sep 2016 Pooled efficacy data from two phase II trials in Volunteers with Renal impairment released by Pernix Therapeutics
  • 29 Jul 2016 Hydrocodone controlled-release - Pernix Therapeutics is available for licensing in (excluding USA) -http://altusformulation.com/intelli-products/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top